Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 24
- Registration Number
- NCT06745882
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLS) (MK-3475-01G/KEYMAKER U01)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT06731907
Safety, Effectiveness, and Pharmacokinetics (the Movement of Drug Into, Through and Out of the Body) of BNT327 (an Investigational Therapy) in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 982
- Registration Number
- NCT06712316
A Study of SKB264 in Combination with Pembrolizumab Versus Chemotherapy in Combination with Pembrolizumab As First-Line Treatment for PD-L1 Negative Patients with Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 432
- Registration Number
- NCT06711900
- Locations
- 🇨🇳
Shanghai Oriental Hospital, Shanghai, China
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 430
- Registration Number
- NCT06704620
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT06694454
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- mAbxience Research S.L.
- Target Recruit Count
- 726
- Registration Number
- NCT06687369
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT06663306
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1100
- Registration Number
- NCT06632327
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 64
- Registration Number
- NCT06630416
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath